Zai Lab Earnings Call: Growth, Pipeline And Volatility

Zai Lab Ltd ((ZLAB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Zai Lab’s latest earnings call painted a picture of a company balancing strong financial momentum with manageable execution risks. Management highlighted solid double‑digit revenue growth, improving margins and a deep pipeline moving quickly into late‑stage studies. While pricing pressure, hospital purchasing swings and regulatory uncertainties cloud the near term, the tone stayed confidently optimistic.

Revenue Growth Underscores Business Momentum

Zai Lab reported fourth‑quarter revenue of $127.6 million, up 17% year over year, and full‑year 2025 revenue of $460.2 million, up 15%. Management framed this growth as proof that the commercial portfolio is scaling, even as some products face supply, pricing and procurement headwinds that could cause quarterly volatility.

Cash Reserves Provide Strategic Flexibility

The company ended the year with $790 million in cash, giving it ample runway to fund upcoming launches and global R&D plans without near‑term financing pressure. For investors, this balance sheet strength underpins Zai Lab’s ability to push multiple late‑stage assets forward while absorbing uneven revenue patterns.

Expense Discipline Improves Operating Leverage

R&D spending declined 6% year over year and SG&A fell 12% in the fourth quarter and 7% for the full year, signaling tighter cost control. As a result, loss from operations improved 19% to $229.4 million and 25% on an adjusted basis, showing progress toward the company’s long‑term profitability goal despite heavy pipeline investment.

Key Commercial Franchises Drive the Top Line

XACDURO, NUZYRA and ZEJULA were standout revenue contributors in the quarter, with ZEJULA buoyed by strong first‑line BRCA‑positive patient starts. XACDURO, in particular, saw robust patient demand and growing hospital adoption, and management suggested that easing supply constraints should better align reported sales with underlying demand.

VYVGART Builds Depth in the Market

Physician confidence and patient demand for VYVGART remain solid, with average treatment cycles per patient rising more than 50% versus 2024 by year‑end. Management is targeting at least three cycles per patient in the near term, a shift that could deepen revenue per patient even if headline volume trends slow.

zoci’s Rapid March to Phase III

The DLL3 antibody‑drug conjugate zoci has moved from IND to a global registrational Phase III trial in less than two years, a pace management repeatedly emphasized. The Phase III study in second‑ and third‑line small‑cell lung cancer will enroll about 480 patients and is supported by early data showing an 80% response rate in 10 patients with untreated brain metastases and a favorable safety profile.

Pipeline Breadth Extends Beyond zoci

Beyond its flagship ADC, Zai Lab advanced several innovative programs, including ZL‑6201, which received U.S. IND clearance and entered global Phase I. Other assets such as ZL‑1222, ZL‑1311 and ZL‑1503 are progressing through IND‑enabling work or early‑stage studies, with the company guiding to first‑in‑human data for ZL‑1503 later this year.

Multiple Late‑Stage Regional Catalysts Lined Up

Management highlighted a series of regional late‑stage events, including an interim readout for povetacicept in IgA nephropathy from the RAINIER Phase III trial in the first half of 2026. Additional catalysts include global REVEAL‑1 top‑line data in the first quarter of 2026 and REVEAL‑2 in the second quarter, alongside ongoing efforts to broaden efgartigimod’s label across autoimmune diseases.

Upcoming Launches Expand the Commercial Platform

Zai Lab is preparing for several new launches, including the planned China approval and rollout of TIVDAK in 2026 and Q2 2026 launches for COBENFY and KarXT. The company also noted recent U.S. approval of Optune Pax in locally advanced pancreatic cancer, underscoring its strategy of layering new products onto an increasingly diversified commercial base.

Short‑Term Pricing and Channel Pressures

Near‑term performance for VYVGART will be tempered by pricing dynamics tied to China reimbursement renewal, competition and potential IV price and rebate adjustments. Management expects only measured growth in 2026 for this asset, while Q4 results already reflected channel noise from hospital purchasing patterns that may recur.

Supply Constraints Mask XACDURO Demand

While XACDURO is gaining hospital traction and patient uptake, supply constraints earlier in the year limited the full revenue potential of the brand. As supply normalizes, investors should watch whether reported sales begin to more accurately reflect the underlying demand trends described on the call.

Competitive and Procurement Headwinds for ZEJULA

ZEJULA must navigate a market now influenced by generics to a key rival and China’s volume‑based procurement rules, which can shift volumes and pricing abruptly. Management cautioned that these dynamics, along with hospital budgeting cycles, could make early‑year ZEJULA revenues lumpy even if overall demand remains sound.

Profitability Timing Remains Open‑Ended

Despite better operating leverage, Zai Lab declined to give full‑year 2026 financial guidance or commit to profitability in that year, citing moving pieces in pricing and investment. Corporate breakeven remains an explicit objective, but management made clear that timing will depend on the pace of top‑line growth versus continued R&D and launch spending.

Regulatory and Enrollment Risks for Global Programs

The company acknowledged uncertainties around zoci’s regulatory path and enrollment timelines, including whether single‑arm data might suffice in certain tumor types and how evolving post‑progression treatments could affect survival analyses. Stratification strategies are intended to limit bias, but investors should expect some variability around the projected 2027 submission and 2028 approval timelines.

Hospital Purchasing to Drive Revenue Volatility

Across the portfolio, management repeatedly flagged hospital budgeting and procurement behavior as a key swing factor for quarterly results in 2026. These channel dynamics, layered on top of NRDL renewals and tender timing, mean investors may see uneven quarter‑to‑quarter revenue even if the underlying trajectory remains positive.

Guidance Frames 2026 as an Execution Year

Management positioned 2026 as a year of disciplined execution and pipeline delivery rather than headline guidance, reiterating 2025 revenue and margin improvements as a base. They expect measured VYVGART growth, ongoing strength from ZEJULA and XACDURO and contribution from planned launches, with SG&A creeping up only modestly and R&D broadly stable as major clinical milestones for zoci and other assets come into focus.

Zai Lab’s earnings call left the impression of a company in transition from regional player to global oncology and autoimmune contender. Strong growth, a fortified balance sheet and rapid pipeline progress are balanced against pricing pressure, hospital procurement volatility and regulatory uncertainty, but management’s tone suggested confidence that long‑term value creation remains on track.